Top Markets
#1 Trillions Trillions +4,371.22%
#2 Ozapay Ozapay +37.63%
#3 UnifAI Network UnifAI Network +26.77%
#4 Aria.AI Aria.AI +21.95%
#5 Zano Zano +17.34%
#6 Osaka Protocol Osaka Protocol +14.21%
#7 StakeStone StakeStone +13.94%
#8 Vestra DAO Vestra DAO +11.91%
#9 River Pts River Pts +10.84%
#10 pippin pippin +10.64%
Coin of the day
Trillions Trillions
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Classement en actions #99999
Acticor Biotech SAS operates as a clinical stage biotechnology company that... Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.
Prix de l'action
$0.28545656
Capitalisation boursière
$4.50M
Changement (1 jour)
5.97%
Changement (1 an)
0.00%
Pays
FR
Échange Acticor Biotech SAS (ALACT)

Catégorie

Healthcare
Bénéfices pour Acticor Biotech SAS (ALACT)
Bénéfices en Jun 2024 TTM : $-12.93M
Selon les derniers rapports financiers de Acticor Biotech SAS, les bénéfices actuels de l'entreprise sont de $-12.93M. En 2022, l'entreprise a réalisé un bénéfice de $-19.33M, une diminution par rapport à celui de 2021 qui était de $-16.54M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Acticor Biotech SAS de 2010 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
2026 (TTM) $-12.93M -43.60%
2023 $-22.92M 18.60%
2022 $-19.33M 16.85%
2021 $-16.54M 50.20%
2020 $-11.01M 86.82%
2019 $-5.89M -14.36%
2018 $-6.88M -41.98%
2017 $-11.86M 2,061.40%
2016 $-548.85K -76.37%
2015 $-2.32M 97.57%
2014 $-1.18M -131.38%
2013 $3.75M -11.81%
2012 $4.25M 30.59%
2011 $3.25M 275.68%
2010 $865.72K 0.00%
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.46B -158,354.90%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$4.64B -36,019.43%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B -40,564.29%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -16,637.04%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -12,587.97%
AU